RxDoctor Payments Data

Eshagh Faraji, MD

Gastroenterology · Turlock, CANPI 1912000811

Payments from drug & device makers

$80,468in general payments, 2019–2025

Across 1,481 payments — averaging $54.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aimmune Therapeutics, Inc.$28K
  • Nestle Healthcare Nutrition Inc.$23K
  • AbbVie$8K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
  • Gilead$3K
  • Johnson & Johnson$3K
  • plus $12K from 38 others

What the payments were for

  • Consulting fees$1,5112%
  • Speaking & faculty fees$44,33855%
  • Travel & lodging$3,5524%
  • Food & beverage$30,90138%
  • Education$880%
  • Gifts$800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,468 in reported general payments places this provider in the 85th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$286,309
Medicare patients
948
Services billed
2,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab53$1,395,468
ZenpepLipase/Protease/Amylase51$241,427
XifaxanRifaximin57$186,559
CreonLipase/Protease/Amylase41$148,316
LinzessLinaclotide64$80,757
Cimzia (2 Pack)Certolizumab Pegol12$63,467
IbsrelaTenapanor Hcl14$56,809
VemlidyTenofovir Alafenamide24$32,369
Dexlansoprazole DrDexlansoprazole70$27,762
NexiumEsomeprazole Magnesium14$12,481
Lubiprostone29$8,457
Pantoprazole Sodium572$8,365
SutabSod Sulf/Pot Chloride/Mag Sulf30$4,859
Mesalamine12$4,284
Ursodiol16$3,850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$2,712$1,395,46853 claims
Aimmune Therapeutics, Inc.Zenpep$27,968$241,42751 claims
AbbVieCreon, Linzess$7,843$229,073105 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$3,738$186,55957 claims
UCB, Inc.Cimzia (2 Pack)$87$63,46712 claims
Ardelyx, Inc.Ibsrela$2,375$56,80914 claims
GileadVemlidy$3,015$32,36924 claims
Braintree Laboratories, Inc.Sutab$488$4,85930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Turlock

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →